ACAD Acadia Pharmaceuticals receives FDA fast track designation for remlifanserin in Alzheimer's Disease psychosis Acadia Pharmaceuticals -

ACAD Acadia Pharmaceuticals receives FDA fast track designation for remlifanserin in Alzheimer's Disease psychosis Acadia Pharmaceuticals - completes radiant phase 2 enrollment; topline results expected September-october 2026 - Begins screening and enrollment for phase 3 studies of remlifanserin